Leptomeningeal metastases (LM), a devastating complication and predictor of poor survival in lung cancer patients, was found to be more prevalent in non-small cell lung cancer (NSCLC) patients with epidermal growth factor ...
Aug 15, 2016
0
0
An FDA approved drug to treat renal cell carcinoma appears to reduce levels of a toxic brain protein linked to dementia in Alzheimer's and Parkinson's diseases when given to animals. This finding is the latest from Georgetown ...
Jul 27, 2016
0
2
A team of CNIO researchers, in collaboration with the Spanish Oncology Genitourinary Group (SOGUG) and the University Hospitals Leuven (Belgium), has discovered various potential biomarkers predictive of tyrosine kinase inhibitors ...
Jul 7, 2016
0
0
Osimertinib has been approved since February 2016 for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC). ...
Jun 20, 2016
0
0
A University of Colorado Cancer Center study presented at the American Association for Cancer Research Annual Meeting 2016 pinpoints ways that cancer cells evolve to resist the drug LOXO-101, a kinase inhibitor of the TRK-fusion ...
Apr 18, 2016
0
4
The benefit of plasma genotyping to predict treatment benefit in patients with non-small-cell lung cancer (NSCLC) is confirmed in three studies presented today at the European Lung Cancer Conference (ELCC) 2016 in Geneva, ...
Apr 15, 2016
0
0
The third generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) osimertinib is effective in the first-line treatment of EGFR mutated non-small-cell lung cancer (NSCLC), according to a late-breaking ...
Apr 14, 2016
0
0
A subset of acute lymphoblastic leukemia (ALL) patients is positive for the Philadelphia chromosome, which is generated by a specific translocation event that causes a fusion between the BCR and ABL1 genes. These patients ...
Apr 7, 2016
0
0
Acute myeloid leukemia (AML) is a cancer of myeloid stem cells that develops in both adult and pediatric populations. Mutations that cause hyperactivation of the FMS-like tyrosine kinase 3 (FLT3) are commonly found in AML, ...
Mar 17, 2016
0
0
With the expiration in January of the patent on Gleevec, the drug that 15 years ago changed chronic myeloid leukemia (CML) from a death sentence to a treatable illness, insurance companies and patients have the opportunity ...
Mar 15, 2016
0
2
